A Comparative Study on the Effects of Nicotine and GTS-21, a New Nicotinic Agonist, on the Locomotor Activity and Brain Monoamine Level | Zendy

toasato Nanri | Zendy; Nobuo Kasahara | Zendy; Jyunji Yamamoto | Zendy; Hidekazu Miyake | Zendy; Takeshi Nabe | Zendy

Open Access

A Comparative Study on the Effects of Nicotine and GTS-21, a New Nicotinic Agonist, on the Locomotor Activity and Brain Monoamine Level

Author(s) -

toasato Nanri,

Nobuo Kasahara,

Jyunji Yamamoto,

Hidekazu Miyake,

Takeshi Nabe

Publication year - 1998

Publication title -

the japanese journal of pharmacology

Language(s) - English

Resource type - Journals

eISSN - 1347-3506

pISSN - 0021-5198

DOI - 10.1254/jjp.78.385

Subject(s) - nicotine , dopamine , dopaminergic , nicotinic agonist , agonist , cholinergic , locomotor activity , monoamine neurotransmitter , pharmacology , striatum , chemistry , medicine , endocrinology , neuroscience , psychology , receptor , serotonin

Effects of GTS-21 [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride], a selective nicotinic agonist, on locomotor activity and dopamine turnover were examined and compared to those of nicotine to test if GTS-21 exhibits side effects similar to those of nicotine. GTS-21 had no effect on locomotor activity in mice or dopamine turnover in rats. In contrast, nicotine produced a biphasic effect on locomotor activity. It also enhanced dopamine turnover rates in the striatum and cerebral cortex, suggesting the involvement of dopaminergic systems in the nicotine-induced changes in locomotor activity. GTS-21 exhibits fewer adverse effects, suggesting that it has therapeutic potential for cognitive disorders related to central cholinergic dysfunction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research